Anti-BCMA Antibody Drug Conjugate Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma are limited by toxic effects and the inevitability of relapse, necessitating the development of new treatment combinations with non-overlapping mechanisms of action and minimal cross-resistance.
Innovation Solution
A combination therapy involving an anti-BCMA antigen binding protein, an immunomodulatory imide drug (IMiD), and optionally an anti-inflammatory compound like dexamethasone, administered in specific dosages and treatment schedules to enhance anticancer efficacy while reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for multiple myeloma are used, then cancer cells are targeted and treated, but toxic effects occur and relapse is inevitable
Solution Approach 1:
The treatment is segmented into multiple distinct components with non-overlapping mechanisms of action: an anti-BCMA antigen-binding protein (targeting BCMA-expressing myeloma cells), an immunomodulatory imide drug (IMiD; modulating immune response), and an anti-inflammatory compound (reducing inflammation). This segmentation allows each component to address different aspects of the disease with minimal cross-resistance and reduced overall toxicity compared to conventional single-mechanism therapies.
Solution Approach 2:
The invention employs a composite therapeutic regimen combining three different drug classes with distinct mechanisms of action. This composite approach creates a synergistic effect where the combination of agents produces greater therapeutic benefit while reducing the toxic effects associated with each individual agent used at standard doses, thereby improving the therapeutic index.
2Reliability
If three and four-drug combinations are used for previously treated MM, then treatment efficacy is improved, but serious toxicity increases
Solution Approach 1:
The invention optimizes the dosing parameters and administration schedule of each component in the combination regimen. By carefully selecting doses that are lower than those used in conventional single-agent therapies, the patent achieves effective cancer cell targeting while maintaining toxicity levels within acceptable ranges. The specific dosing regimen is calibrated to maximize therapeutic benefit while minimizing harmful effects.
3Reliability
If treatments with overlapping mechanisms of action are used, then cancer is treated, but cross-resistance develops
Solution Approach 1:
The treatment regimen is segmented into components with distinctly different mechanisms of action: the anti-BCMA antigen-binding protein targets BCMA-expressing cells directly, the IMiD modulates immune system activity, and the anti-inflammatory compound reduces inflammatory responses. This mechanistic segmentation ensures that resistance to one component does not confer cross-resistance to the others, maintaining treatment efficacy even in previously treated patients.
Data Source
AI summary
Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).